Aurinia Pharmaceuticals Inc. (AUPH)
Makes medicines that treat lupus and other autoimmune diseases.
$14.96-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+42.6%
The outlook
Aurinia trades at $14.96, positioned roughly midway through its 52-week range but below both its 50- and 200-day moving averages. Analysts lean bullish with a "Buy" consensus and an average price target about 14% above current levels. The stock carries a notably low trailing P/E of 6.9, though recent price momentum appears subdued.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +14% vs current price
Analyst price target
~12-month · 7 analysts$17.00average target+13.6% vs now
Now $14.96
Low $15.00High $21.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.92B
52-wk high
$19.25
52-wk low
$8.80
50-day avg
$15.98
200-day avg
$15.08
Trailing P/E
6.9